Drugs / Polyclonal immunoglobulin
last change Jun 2021 re-read 2 minutes ago

Polyclonal immunoglobulin

Developed for
COVID-19
Investigated by
Fundacion Clinic per a la Recerca Biomédica

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04374539 Apr 2020 → Jun 2021 COVID-19 Fundacion Clinic per a la Recerca Biomédica Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Polyclonal immunoglobulin Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.” NCT04374539
Route Intravenous “administered at a dose of 100 mg / kg ev” NCT04374539